OncLive | Anti-CD20 Antibodies Continue to Improve Outlook in CLL OncLive In 2006, Rituximab became the first anti-CD20 antibody to be approved for the treatment of hematologic malignancies and quickly became part of the armamentarium for the treatment of patients with CLL. “Ofatumumab was approved a few years ago, and ... |
